Amneal receives u.s. fda approval for calcium gluconate injection

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced it has received abbreviated new drug application (“anda”) approval from the u.s. food and drug administration (“fda”) for calcium gluconate in sodium chloride injection, 1000 mg/50 ml and 2000 mg/100 ml. this injectable product is currently on the u.s. fda shortage product list. the product approval received the fda's competitive generic therapy (“cgt”) designation with 180-.
AMRX Ratings Summary
AMRX Quant Ranking